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Summary
Steroidogenic acute regulatory protein (STAR) is a key protein for the intracellular transport of cholesterol to the 
mitochondrium in endocrine organs (e.g. adrenal gland, ovaries, testes) and essential for the synthesis of all steroid 
hormones. Several mutations have been described and the clinical phenotype varies strongly and may be grouped into 
classic lipoid congenital adrenal hyperplasia (LCAH), in which all steroidogenesis is disrupted, and non-classic LCAH, 
which resembles familial glucocorticoid deficiency (FGD), which affects predominantly adrenal functions. Classic LCAH 
is characterized by early and potentially life-threatening manifestation of primary adrenal insufficiency (PAI) with 
electrolyte disturbances and 46,XY disorder of sex development (DSD) in males as well as lack of pubertal development in 
both sexes. Non-classic LCAH manifests usually later in life with PAI. Nevertheless, life-long follow-up of gonadal function 
is warranted. We describe a 26-year-old female patient who was diagnosed with PAI early in life without detailed 
diagnostic work-up. At the age of 14 months, she presented with hyperpigmentation, elevated ACTH and low cortisol 
levels. As her older brother was diagnosed with PAI two years earlier, she was put on hydrocortisone and fludrocortisone 
replacement therapy before an Addisonian crisis occurred. Upon review of her case in adulthood, consanguinity was 
noted in the family. Genetic analysis for PAI revealed a homozygous mutation in the STAR gene (c.562C>T, p.Arg188Cys) 
in both siblings. This mutation has been previously described in non-classic LCAH. This case illustrates that early onset, 
familial PAI is likely due to autosomal recessive genetic mutations in known genes causing PAI.
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Learning points:
 • In childhood-onset PAI, a genetic cause is most likely, especially in families with consanguinity.
 • Adult patients with an etiologically unsolved PAI should be reviewed repeatedly and genetic work-up should be 
considered.
 • Knowing the exact genetic diagnosis in PAI is essential for genetic counselling and may allow disease-specific 
treatment.
 • Young men and women with NCLAH due to homozygous STAR Arg188Cys mutation should be investigated for 
their gonadal function as hypogonadism and infertility might occur during puberty or in early adulthood.
Downloaded from Bioscientifica.com at 02/26/2019 01:08:25PM
via Universitaetsbibliothek Bern and Universitat Bern
L Burget and others Primary adrenal insufficiency 
due to STAR mutation
ID: 18-0003; March 2018
DOI: 10.1530/EDM-18-0003
http://www.edmcasereports.com 2
Background
Primary adrenal insufficiency (PAI) comprises a 
large group of rare disorders with a broad spectrum 
of pathomechanisms and clinical phenotypes, e.g. 
syndromic and non-syndromic forms (1). In general, 
PAI is characterized by a lack or deficiency of production 
of adrenal steroids, specifically glucocorticoids, with 
consecutive activation of the CRH–ACTH axis and also, 
in case of concomitant mineralocorticoid deficiency, a 
negative feedback activation of the renin-angiotensin 
system. While in childhood genetic forms predominate, 
autoimmune PAI is the diagnosis most often found in 
adults. Overall, congenital adrenal hyperplasia (CAH) due 
to 21-hydroxylase deficiency (CYP21A2 gene) is the most 
common form of genetic PAI (2). However, the etiologic 
spectrum comprises not only defects of steroid hormone 
biosynthesis, but also syndromes, adrenal dysgenesis, 
disorders characterized by ACTH resistance (also known 
as familial glucocorticoid deficiencies (FGD)), metabolic 
conditions with mitochondrial or peroxisomal defects, as 
well as disorders of cholesterol synthesis (3). Replacement 
therapy with glucocorticoids and mineralocorticoids, 
as needed, is essential, but remains often challenging 
with chronic overtreatment resulting in Cushings and 
undertreatment increasing the risk for a life-threatening 
Addison crisis (4).
 • This case illustrates that work-up of an etiologically 
unsolved PAI in an adult patient might be complicated 
and only be solved by genetic analysis. Clinical signs 
and laboratory results are not precise enough and do 
overlap with other forms of PAI.
 • To our knowledge, the diagnosis ‘PAI of unknown 
etiology’ does not automatically implicate gonadal 
insufficiency and might be neglected in the absence of 
a genetic diagnosis. Although gonadal function seems 
to be unaffected in our female patient so far, it appears 
to be impaired in her older brother. In other cases with 
homozygous Arg188Cys mutation, hypogonadism and 
infertility were reported. Close surveillance of gonadal 
function and discussion of possible preventive fertility 
measures (e.g. cryopreservation of sperms or oocytes) 
should be offered.
 • Finding the appropriate dose of glucocorticoid and 
mineralocorticoid replacement therapy is often 
difficult, even in patients with PAI due to identical 
STAR mutations, e.g. Arg188Cys. Thus, genotype and 
phenotype do not correlate well. Individual dosing 
of drugs according to well-being of the patient seems 
essential. ACTH levels seem irrelevant as they tend 
to remain high despite adequate substitution with 
physiological or even supraphysiological doses of 
glucocorticoids.
Case presentation
A 26-year-old 46,XX female with childhood-onset PAI of 
unknown genetic cause was regularly seen at the outpatient 
clinic of endocrinology. Her two years older brother was 
diagnosed with PAI shortly after birth and started on 
treatment with glucocorticoids and mineralocorticoids. 
Initially, no signs of PAI were evident in the girl but at the 
age of 14 months, detailed investigations were performed 
due to progressive hyperpigmentation of the skin. Body 
weight was 9 kg (25th–50th percentile), height 72 cm (10th 
percentile) and head circumference 47 cm (75th–90th 
percentile). Laboratory analyses showed normal plasma 
sodium (143 nmol/L; ref. values: 136–145) and potassium 
(4.9 nmol/L, ref. value: 3.5–5.0) levels, while chloride 
(106 nmol/L, 95–105) was just above normal. Bicarbonate 
was decreased (20.3 nmol/L, ref. values: 22–28) and glucose 
normal (4.2 nmol/L, ref. values: 4.1–5.5). Hormonal 
analyses showed the constellation of subclinical PAI with 
elevated ACTH (>1500 ng/L, ref. values: 7.3–50.4), but 
normal cortisol (149 nmol/L, ref. values: 55–690 nmol/L). 
Renin activity was increased (30.1 ng/mL/h, ref. values: 
1.4–7.8) with normal aldosterone (647 pmol/L; ref. values: 
180.3–2385). Testing for 21-hydroxylase antibodies was 
negative. Replacement therapy with 50 µg fludrocortisone 
daily and 10 mg hydrocortisone (20 mg/m2/day) was 
initiated.
She was then regularly followed by the pediatric 
endocrinologist throughout her childhood without any 
reported abnormalities. At the age of 16 years, her height 
was 159 cm (10th–25th percentile) and weight 72 kg 
(90th–97th percentile). Blood pressure was 130/85 mmHg. 
Secondary sex characteristics were fully developed and 
normal menstrual cycles were reported. At that age 
transition to adult endocrine care was performed. In the 
following years, doses of hydrocortisone were repeatedly 
adjusted because of elevated ACTH levels (>300 pmol/L) 
and progressive hyperpigmentation of the skin on one 
hand and because of weight problems and to avoid 
Cushings on the other. Because of elevated blood pressure, 
fludrocortisone was temporarily stopped at the age of 
19 years without prompting hypotension, orthostasis or 
hyperkalemia, but restarted two years later in order to 
save on hydrocortisone dose.
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Investigation
Current follow-up at the age of 26  years revealed no 
signs of cognitive or physical disabilities. She had a 
normal medical history concerning working and exercise 
capacity. Menstrual cycles were regular without hormonal 
contraception. Physical examination revealed a 1.60 m tall 
and slightly overweight (BMI: 28.1 kg/m2) female patient. 
Blood pressure was 130/80 mmHg, pubertal development 
was adult, corresponding to Tanner stage V. Generalized 
hyperpigmentation of the skin was noted, predominately 
periorbital, in the hand lines, and the dorsal and plantar 
parts of the knees and joints. Under daily treatment with 
25 mg hydrocortisone and 50 µg fludrocortisone, ACTH 
levels were increased (360 pmol/L; ref. values: 2.2–10.6). 
Renin levels were in normal range with 17.9 ng/L (ref. 
values: 2.6–27.2). Further laboratory work-up revealed 
normal electrolytes, normal HbA1c and a normal lipid 
profile. There were no signs of Cushings, especially no 
abdominal obesity.
Outcome and follow-up
Upon review of the case, consanguinity was noticed in 
the family and genetic testing for non-syndromic forms 
of PAI/FGD was recommended and performed after 
obtaining written informed consent.
PCR-based candidate gene testing was performed 
on genomic DNA extracted from blood leukocytes as 
described (5). Analyses for possible MC2R and MRAP 
mutations (FGD) were negative and a homozygous, single 
nucleotide change was found in the STAR gene (c.562C>T, 
p.Arg188Cys). The same homozygous mutation was also 
detected in her brother, while both parents were found to 
be heterozygous carriers of the mutation.
Discussion
Rare causes of PAI are linked to a growing number of genetic 
diseases and are either isolated adrenal disorders or part 
of a syndrome spectrum. Some of these genetic disorders 
are long known, while others have only been discovered 
recently. In a recently published large Turkish cohort, a 
genetic diagnosis was found in 81% (77/95) of children 
with PAI, in whom CAH, X-linked adrenoleukodystrophy, 
autoimmune triggered PAI, as well as known syndromic 
causes had been previously excluded (4). Different STAR 
mutations were detected in 11/95 children (6).
STAR is essential for the transport of cholesterol to 
the inner mitochondrial membrane of steroid producing 
organs (e.g. adrenal gland, ovaries and testes). More than 
35 mutations are described so far. Clinical phenotype of 
patients with autosomal recessive STAR mutations varies 
considerably, but may be grouped in classic congenital lipoid 
adrenal hyperplasia (CLAH), where all steroidogenesis 
is disrupted, and non-classic CLAH (NCLAH), where 
typically only adrenal steroidogenesis is disrupted and 
thus an overlap with familial glucocorticoid deficiency 
(FGD) syndromes exists (7). CLAH is characterized by 
early and maybe life-threatening manifestation of adrenal 
insufficiency with fatal electrolyte shifts and a 46,XY 
disorder of sex development (DSD) in males as well as a 
lack of pubertal development in both sexes. By contrast, 
NCLAH manifests generally later as an adrenal deficiency 
phenotype only, although life-long follow-up of gonadal 
function is warranted. To date, 9 STAR mutations causing 
NCLAH have been reported. The Arg188Cys mutation 
(found in our patient) has been described in 7 families. 
Its in vitro activity assessed by pregnenolone production 
from cholesterol in cell models ranges from 8 to 14% 
compared to the wild-type STAR protein.
In our patient, glucocorticoid deficiency was 
confirmed repeatedly in lab tests, which is consistent with 
other cases harboring the Arg188Cys mutation (8). Mild 
mineralocorticoid deficiency was also demonstrated after 
fludrocortisone withdrawal, when plasma renin levels 
increased. Other patients with the Arg188Cys mutation 
showed inconsistently mineralocorticoid deficiency. 
Hence, the need for replacement of mineralocorticoids 
must be evaluated for every case individually, and may 
depend on salt intake (8).
In our female patient, sex steroid production 
does not seem to be affected so far; she reports regular 
menstrual cycles. In the literature, data on sex steroids 
and fertility in NCLAH are highly divergent. Therefore, 
regular evaluation of ovarian function and, if abnormal, 
timely hormonal replacement and possibility of oocyte 
preservation may be recommended.
The brother of our patient refused endocrine follow-up. 
He was last seen at the age of 18  years by the pediatric 
endocrinologist. Normal adult pubertal development was 
found. Interestingly, a handwritten note, which was found in 
the sister’s record revealed possible male hypergonadotropic 
hypogonadism when he was in his early twenties. In 
other cases of homozygous Arg188Cys mutation, a broad 
range of impact on sex steroid synthesis and fertility is 
described. In boys and men, normal pubertal development 
and fatherhood as well as bilateral cryptorchidism and 
hypergonadotropic hypogonadism have been reported (9). 
Male fertility seems to be compromised by atrophy or lipid 
droplets in Leydig cells and reduced spermatogenesis (9). 
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In women, regular menstrual cycles seem to be preserved, 
but successful pregnancy was not reported so far (8). The 
‘two-hit model’ of LCAH suggests that Leydig cells in the 
testes are earlier damaged by lipid deposition because 
LH-driven steroidogenesis begins prenatally, continues 
after birth and is not silenced until puberty, as it is the 
case for steroidogenesis of the granulosa/theca cells in the 
ovaries (10).
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